CritiTech

Executive Summary

CritiTech is a private US-based CDMO/CRO specializing in particle engineering to enhance drug solubility and bioavailability, with a focus on oncology and inhaled drug delivery. Founded in 1997 and headquartered in Lawrence, Kansas, the company offers services from early-stage pre-formulation through GMP commercial manufacturing. Its core technology addresses the critical challenge of poorly water-soluble drugs, a bottleneck in many drug development programs. By leveraging advanced particle size reduction and formulation techniques, CritiTech enables clients to accelerate timelines and improve therapeutic outcomes. The company's expertise in oncology and inhalation aligns with high-growth areas in pharmaceuticals, positioning it as a valuable partner for biotech and pharma firms seeking to bring novel therapies to market. As a contract organization, CritiTech's revenue is driven by project-based fees, with growth tied to the number and scale of client engagements. While financial data is not publicly disclosed, the company's longevity (over 25 years) suggests a stable track record. The demand for specialized CDMO services remains strong, particularly for complex formulations like inhaled oncology drugs. However, competition from larger CDMOs and reliance on client spending cycles present risks. Overall, CritiTech occupies a niche but essential role in the drug development value chain, with moderate growth prospects contingent on industry trends and operational execution.

Upcoming Catalysts (preview)

• Q3 2026New oncology inhalation client contract60% success
• Q4 2026Expansion of GMP manufacturing capacity50% success
• Q2 2026Strategic partnership for particle engineering IP licensing40% success